KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2017 - 2025)

Arbutus Biopharma (ABUS) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $2.9 million as the latest value for Q1 2025.

  • Quarterly Non-Current Deffered Revenue changed N/A to $2.9 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Mar 2025, changed N/A year-over-year, with the annual reading at $2.9 million for FY2024, N/A changed from the prior year.
  • Non-Current Deffered Revenue hit $2.9 million in Q1 2025 for Arbutus Biopharma, roughly flat from $2.9 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $15.6 million in Q1 2022 to a low of $2.9 million in Q4 2024.
  • Historically, Non-Current Deffered Revenue has averaged $7.4 million across 4 years, with a median of $6.0 million in 2022.
  • Biggest YoY gain for Non-Current Deffered Revenue was 78.85% in 2023; the steepest drop was 78.85% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $6.0 million in 2022, then crashed by 45.06% to $3.3 million in 2023, then fell by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for ABUS at $2.9 million in Q1 2025, $2.9 million in Q4 2024, and $3.3 million in Q1 2023.